Ultragenyx Pharmaceutical Inc. (RARE): R&D Expense
$750.00M
Year ended 2025-12-31
+2.0%
3-year compound annual growth
+12.7%
5-year compound annual growth
+20.7%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $750.00M | +7.4% | 2026-02-18, From 2025-01-01 |
| 2024-12-31 | $698.00M | +7.7% | 2026-02-18, From 2024-01-01 |
| 2023-12-31 | $648.00M | -8.2% | 2026-02-18, From 2023-01-01 |
| 2022-12-31 | $705.79M | +42.0% | 2025-02-19, From 2022-01-01 |
| 2021-12-31 | $497.15M | +20.6% | 2024-02-21, From 2021-01-01 |
| 2020-12-31 | $412.08M | +15.3% | 2023-02-17, From 2020-01-01 |
| 2019-12-31 | $357.36M | +21.6% | 2022-02-15, From 2019-01-01 |
| 2018-12-31 | $294.00M | +26.9% | 2021-02-12, From 2018-01-01 |
| 2017-12-31 | $231.64M | +26.4% | 2020-02-14, From 2017-01-01 |
| 2016-12-31 | $183.20M | +59.7% | 2019-02-20, From 2016-01-01 |
| 2015-12-31 | $114.74M | +149.6% | 2018-02-21, From 2015-01-01 |
| 2014-12-31 | $45.97M | +65.2% | 2017-02-17, From 2014-01-01 |
| 2013-12-31 | $27.83M | +120.1% | 2016-02-26, From 2013-01-01 |
| 2012-12-31 | $12.64M | n/a | 2015-03-27, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $750.00M | +7.4% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $96.85M | -13.2% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $183.28M | -2.0% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $106.23M | -2.4% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $85.84M | +16.1% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $117.31M | +43.8% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $160.22M | +69.9% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $53.20M | -24.8% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $124.03M | +17.9% |
Compare RARE, KNSA, AXSM, SUPN side by side · Screen every company in Pharmaceutical Preparations ↗